Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Lorazepam
Drug ID BADD_D01318
Description Lorazepam is a short-acting and rapidly cleared benzodiazepine used commonly as a sedative and anxiolytic.[A957] It was developed by DJ Richards, presented and marketed initially by Wyeth Pharmaceuticals in the USA in 1977. The first historic FDA label approval is reported in 1985 by the company Mutual Pharm.[L5095]
Indications and Usage Lorazepam is FDA-approved for the short-term relief of anxiety symptoms related to anxiety disorders and anxiety associated with depressive symptoms such as anxiety-associated insomnia. It is as well used as an anesthesia premedication in adults to relieve anxiety or to produce sedation/amnesia and for the treatment of status epilepticus.[T385] Some off-label indications of lorazepam include rapid tranquilization of an agitated patient, alcohol withdrawal delirium, alcohol withdrawal syndrome, muscle spasms, insomnia, panic disorder, delirium, chemotherapy-associated anticipatory nausea and vomiting, and psychogenic catatonia.[T385]
Marketing Status approved
ATC Code N05BA06
DrugBank ID DB00186
KEGG ID D00365
MeSH ID D008140
PubChem ID 3958
TTD Drug ID D0E0OG
NDC Product Code 0641-6047; 0641-6049; 0904-6008; 71554-009; 72166-001; 0093-3426; 0121-0770; 52427-663; 55154-7976; 60687-638; 65162-018; 68788-7533; 69315-904; 70518-0275; 70518-0445; 0641-6002; 0641-6048; 72789-236; 76329-8261; 0904-6007; 51927-0195; 67763-101; 76420-296; 0093-3427; 52427-661; 61919-062; 63187-536; 67296-1478; 67296-1622; 68071-5022; 0409-6778; 71205-235; 71335-1467; 71610-600; 72572-380; 0641-6000; 0641-6001; 0641-6003; 0641-6051; 48087-0076; 51927-1005; 55154-7975; 61919-607; 67296-1332; 67544-142; 71610-008; 71610-654; 71610-655; 58118-1095; 63304-773; 65162-687; 68071-4916; 68071-5250; 70518-0486; 70518-2186; 70518-2442; 71205-228; 71335-0329; 71335-1455; 71335-1694; 0641-6207; 57218-950; 0187-0064; 53002-5291; 58118-0904; 60760-516; 63187-576; 68071-2666; 70934-782; 72789-197; 72789-226; 0904-6009; 13107-085; 0187-0065; 50383-705; 54348-049; 60687-627; 60687-649; 63304-774; 65162-015; 71335-1138; 71610-255; 12828-0025; 0093-3425; 53002-6290; 67544-191; 68071-3096; 0409-1985; 68788-7355; 70518-1275; 70518-3188; 70518-3423; 71205-166; 71205-756; 71610-122; 71610-229; 71610-674; 0641-6044; 0641-6046; 0641-6050; 64330-020; 43353-255; 52427-658; 55154-7977; 63304-772; 68788-7428; 69315-906; 70518-2268; 70518-3225; 72189-351; 17478-040; 52427-667; 55700-778; 65162-017; 67544-261; 70518-1520; 0054-3532; 71335-0655; 49452-4140; 51552-0729; 13107-083; 50090-5508; 63629-2953; 68071-2662; 68071-3121; 68071-5068; 69315-905; 71610-178; 71610-199; 71610-225; 0641-6045; 52696-0002; 62991-1682; 13107-084; 45865-499; 0187-0063; 50090-5509; 58118-1096
UNII O26FZP769L
Synonyms Lorazepam | Ativan | Orfidal Wyeth | Wyeth, Orfidal | Témesta | Tolid | Donix | Duralozam | Durazolam | Idalprem | Laubeel | Lorazep Von Ct | Von Ct, Lorazep | Lorazepam Medical | Medical, Lorazepam | Lorazepam-Neuraxpharm | Lorazepam Neuraxpharm | Lorazepam-Ratiopharm | Lorazepam Ratiopharm | Novo-Lorazem | Novo Lorazem | Nu-Loraz | Nu Loraz | Sedicepan | Sinestron | WY-4036 | WY 4036 | WY4036 | Apo-Lorazepam | Apo Lorazepam | Somagerol | Temesta
Chemical Information
Molecular Formula C15H10Cl2N2O2
CAS Registry Number 846-49-1
SMILES C1=CC=C(C(=C1)C2=NC(C(=O)NC3=C2C=C(C=C3)Cl)O)Cl
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Hallucination, visual19.10.04.0070.000092%Not Available
Headache17.14.01.001--
Hemiparesis17.01.04.0010.000083%
Hepatic cirrhosis09.01.04.0010.000083%Not Available
Hepatic encephalopathy17.13.01.003; 09.01.03.0060.000114%Not Available
Hepatitis09.01.07.0040.000046%Not Available
Hepatitis acute09.01.07.0050.000031%Not Available
Hepatocellular injury09.01.07.008--Not Available
Hernia08.01.04.001--Not Available
Hostility19.05.01.003--Not Available
Hypercalcaemia14.04.01.003; 05.04.01.0020.000031%
Hypercapnia22.02.02.002; 14.01.04.0010.000259%Not Available
Hyperhidrosis23.02.03.004; 08.01.03.0280.000490%
Hyperkalaemia14.05.03.0010.000108%
Hyperpyrexia08.05.02.0020.000046%Not Available
Hyperreflexia17.02.01.0020.000077%Not Available
Hypersensitivity10.01.03.003--
Hypersomnia19.02.05.001; 17.15.01.0010.000046%
Hypertension24.08.02.001--
Hyperthermia08.05.01.001; 12.05.01.0020.000139%Not Available
Hyperventilation22.02.01.006; 19.01.02.0040.000068%Not Available
Hypervolaemia02.05.04.019; 14.05.06.0030.000031%Not Available
Hypoaesthesia23.03.03.081; 17.02.06.023--Not Available
Hypochromic anaemia01.03.02.004--Not Available
Hypocoagulable state01.01.02.0040.000062%Not Available
Hypoglycaemia14.06.03.001; 05.06.03.0010.000108%
Hypokinesia17.01.02.0090.000601%Not Available
Hypomania19.16.02.0010.000031%Not Available
Hyponatraemia14.05.04.0020.000354%
Hyporeflexia17.02.01.0030.000099%
The 6th Page    First    Pre   6 7 8 9 10    Next   Last    Total 17 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene